专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0026248A3 TUBERCULOSIS DIAGNOSTIC TEST 审中-公开
标题翻译：管腔诊断测试
公开(公告)号：WO0026248A3
公开(公告)日：2001-10-11
申请号：PCT/GB9903635
申请日：1999-11-03
申请人： ISIS INNOVATION , LALVANI AJIT , PATHAN ANSAR AHMED
发明人： LALVANI AJIT , PATHAN ANSAR AHMED
IPC分类号： G01N33/53 , A61K38/00 , A61K48/00 , A61K49/00 , C07K14/35 , C12N15/09 , C12Q1/02 , C12R1/32 , G01N33/569 , A61K31/70 , A61K38/10 , C07K7/08 , C07K16/12 , C12Q1/68 , G01N33/68
CPC分类号： G01N33/6893 , A61K38/00 , A61K48/00 , C07K14/35 , G01N33/5695 , Y10S435/975
摘要： A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may be performed in vivo. Peptides and a kit which enable the method to be carried out are provided.
摘要翻译：一种通过或暴露于表达ESAT-6的分枝杆菌的宿主感染进行诊断的方法，其包括（i）使来自宿主的T细胞群与选自SEQ ID NO：1所示的肽的一种或多种肽或类似物接触至11及其类似物，其可以结合识别任何所述肽的T细胞受体，和（ii）确定所述T细胞群体的T细胞是否识别所述肽和/或类似物。该方法可以在体内进行。提供了能够实施该方法的肽和试剂盒。

2. 发明申请

WO2005090988A2 DIAGNOSTIC TEST 审中-公开
标题翻译：诊断测试
公开(公告)号：WO2005090988A2
公开(公告)日：2005-09-29
申请号：PCT/GB2005001062
申请日：2005-03-21
申请人： ISIS INNOVATION , LALVANI AJIT
发明人： LALVANI AJIT
IPC分类号： G01N33/569 , G01N33/68
CPC分类号： G01N33/5695 , G01N33/6866 , G01N2333/35 , G01N2333/57
摘要： The invention provides a method of diagnosing Mycobacterium tuberculosis infection in a human, or of determining whether a human has been exposed to Mycobacterium tuberculosis, comprising: (i) contacting T-cells from said human with one or more of (a) a peptide having the sequence shown in SEQ ID NO: 1; (b) a peptide having or comprising the sequence of at least 8 consecutive amino acids of the sequence shown in SEQ ID NO: 1; or (c) a peptide having or comprising a sequence which is capable of binding to a T-cell receptor which recognises a peptide as defined in (a) or (b); and (ii) determining whether any of the said T-cells recognise said peptide, wherein steps (i) and (ii) are optionally carried out in vitro.
摘要翻译：本发明提供了诊断人类结核分枝杆菌感染或确定人已经暴露于结核分枝杆菌的方法，其包括：（i）将来自所述人类的T细胞与（a）具有 SEQ ID NO：1所示的序列; （b）具有或包含SEQ ID NO：1所示序列的至少8个连续氨基酸序列的肽; 或（c）具有或包含能够与识别（a）或（b）中定义的肽的T细胞受体结合的序列的肽; 和（ii）确定所述T细胞中的任一个是否识别所述肽，其中步骤（i）和（ii）任选地在体外进行。

3. 发明申请

WO2004005925A3 DIAGNOSTICS METHOD 审中-公开
标题翻译：诊断方法
公开(公告)号：WO2004005925A3
公开(公告)日：2004-03-18
申请号：PCT/GB0302936
申请日：2003-07-07
申请人： ISIS INNOVATION , LALVANI AJIT , EWER KATIE
发明人： LALVANI AJIT , EWER KATIE
IPC分类号： C07K7/08 , G01N33/50 , G01N33/564 , G01N33/569
CPC分类号： G01N33/505 , G01N33/5695
摘要： Method of diagnosing in an individual recent exposure to an agent which is a pathogen, vaccine or any other moiety which induces a cellular response, said method comprising determining in vitro whether the T cells of the individual recognise a protein from said agent having a length of at least 30 amino acids, to a greater extent than one or more peptide epitopes from the agent, a greater extent of recognition of the protein indicating that the individual has recently been exposed to the agent.
摘要翻译：在最近暴露于作为病原体，疫苗或诱导细胞应答的任何其他部分的试剂的个体中进行诊断的方法，所述方法包括在体外确定个体的T细胞是否识别来自所述试剂的蛋白质，其长度为至少30个氨基酸，比来自该试剂的一个或多个肽表位更大的程度，更大程度的蛋白质识别表明个体最近已经暴露于该试剂。

4. 发明申请

WO02054072A3 ASSAY TO DETERMINE EFFICACY OF TREATMENT FOR MYCOBACTERIAL INFECTION 审中-公开
标题翻译：测定治疗感染性肝炎的效果
公开(公告)号：WO02054072A3
公开(公告)日：2003-12-18
申请号：PCT/GB0200055
申请日：2002-01-08
申请人： ISIS INNOVATION , LALVANI AJIT
发明人： LALVANI AJIT
IPC分类号： G01N33/53 , A61K45/00 , A61P31/06 , C07K7/08 , C07K14/30 , C12Q1/02 , G01N33/48 , G01N33/50 , G01N33/569
CPC分类号： G01N33/5695 , G01N33/505 , G01N2800/52
摘要： Method of determining the efficacy of treatment for mycobacterial infection in an individual comprising determining in samples from the individual whether the level of T cells specific for a mycobacterial antigen has decreased after the treatment, thereby determining the efficacy of the treatment.
摘要翻译：确定个体中分枝杆菌感染治疗功效的方法，其包括在来自个体的样品中测定处理后分枝杆菌抗原特异性的T细胞的水平是否降低，从而确定治疗的功效。

5. 发明申请

WO9526982A3 MALARIA PEPTIDES 审中-公开
公开(公告)号：WO9526982A3
公开(公告)日：1996-02-15
申请号：PCT/GB9500737
申请日：1995-03-30
申请人： ISIS INNOVATION , HILL ADRIAN VIVIAN SINTON , AIDOO MICHAEL , ALLSOPP CATHERINE ELIZABETH MA , LALVANI AJIT , PLEBANSKI MAGDALENA , WHITTLE HILTON CARTER
发明人： HILL ADRIAN VIVIAN SINTON , AIDOO MICHAEL , ALLSOPP CATHERINE ELIZABETH MA , LALVANI AJIT , PLEBANSKI MAGDALENA , WHITTLE HILTON CARTER
IPC分类号： C12N15/09 , A61K39/00 , A61K39/015 , A61P33/02 , C07H21/04 , C07K14/445 , C12N5/08 , C12N5/10 , C12N15/30
CPC分类号： C07K14/445 , A61K39/00
摘要： 8-11-Mer peptides are identified, from four Plasmodium falciparum antigens, circumsporozoite protein, thrombospondin-related anonymous protein, spirozoite hepatocyte binding antigen and liver-stage antigen-1, as actual or potential cytotoxic T lymphocyte epitopes for human leucocyte antigen class I molecules HLA-A2, HLA-B8, HLA-B7 and HLA-B17. Vaccines for immunization against malaria contain these peptides or oligonucleotides coding for them. A method of inducing primary cytotoxic T lymphocyte responses to a chosen antigen or microorganism comprises incubating lymphocytes ex vivo with the chosen antigen or microorganism in the presence of keyhole limpet haemocyanin.

6. 发明申请

WO2009150421A3 COMPOSITION FOR THE TREATMENT OF HAIR LOSS AND BALDNESS 审中-公开
标题翻译：用于治疗头发损失和损伤的组合物
公开(公告)号：WO2009150421A3
公开(公告)日：2011-05-19
申请号：PCT/GB2009001456
申请日：2009-06-11
申请人： TAYLOR ROBERT PETER , LALVANI KARTAR SINGH , LALVANI AJIT
发明人： TAYLOR ROBERT PETER , LALVANI KARTAR SINGH , LALVANI AJIT
IPC分类号： A61Q7/00 , A61K8/42 , A61K8/43 , A61K8/49 , A61K8/67 , A61K8/92
CPC分类号： A61Q7/00 , A61K8/42 , A61K8/43 , A61K8/49 , A61K8/4926 , A61K8/671 , A61K8/922 , Y10S514/88
摘要： A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion : 1600 - 2400 IU / mL Vitamin A Palmitate, 0.64% - 0.96 % Thiamine Hydrochloride, 0.64% - 0.96 % Pyridoxine Hydrochloride, 4.8% - 7.2 % Niacinamide, 2.85% - 5.2 % D-Panthenol, 1.6% - 2.4 % L-Arginine, 3.6% - 4.4% Methyl Sulphonyl Methane (MSM), 0.08% - 0.12 % Ginger Oil, 0.08% - 0.12% Cinnamon Oil, 0.0996% - 0.1494% Oleoresin Capsicum, 1.3% - 1.95 % Magnesium, 2.4% - 3.6 % Zinc, 0.192% - 0.288 % Manganese, 2.6% - 3.9 % Urea, 2.4% - 3.6% Sodium Glycerophosphate, 4.8% - 7.2 % L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).
摘要翻译：协同组合物或该组合物在制备药物中的用途或包括使用该组合物在治疗脱发和秃发中的治疗方法，以任何形式的组合，顺序或同时给药，通过任何生物学途径。在其最佳实施方案中，组合物以洗剂的形式组成：1600-2400IU / mL维生素A棕榈酸酯，0.64％-0.96％盐酸硫胺素，0.64％-0.96％盐酸吡哆醇，4.8％-7.2％烟酰胺，2.85％ - 5.2％D-泛醇，1.6％-2.4％L-精氨酸，3.6％-4.4％甲基磺酰甲烷（MSM），0.08％-0.12％姜油，0.08％-0.12％肉桂油，0.0996％-0.1494％油树脂辣椒，1.3％〜1.95％镁，2.4％〜3.6％锌，0.192％〜0.288％锰，2.6％〜3.9％尿素，2.4％〜3.6％甘油磷酸钠，4.8％〜7.2％L-赖氨酸盐酸盐，加防腐剂，共溶剂（丙二醇），香料，抗氧化剂，冷却剂（薄荷醇），乳化剂和载体（纯化水）。

7. 发明申请

WO2007107714A2 CLINICAL CORRELATES 审中-公开
标题翻译：临床相关
公开(公告)号：WO2007107714A2
公开(公告)日：2007-09-27
申请号：PCT/GB2007000934
申请日：2007-03-16
申请人： LALVANI AJIT , MILLINGTON KERRY
发明人： LALVANI AJIT , MILLINGTON KERRY
IPC分类号： G01N33/569
CPC分类号： G01N33/5695 , G01N33/56905 , G01N33/56911 , G01N33/56983 , G01N2333/35 , G01N2333/55 , G01N2333/57 , G01N2800/52
摘要： A method of assessing an intracellular pathogen infection and/or monitoring an intracellular pathogen infection in an individual comprises determining whether the individual has (a) T-cells that secrete IFN-? only, (b) T-cells that secrete IL-2 only or (c) T-cells that secrete both IFN-? and IL-2 in response to an intracellular pathogen antigen and optionally determining any change in this cytokine profile.
摘要翻译：评估个体中细胞内病原体感染和/或监测细胞内病原体感染的方法包括确定个体是否具有（a）分泌IFN-γ的T细胞，（b）仅分泌IL-2的T细胞或（c）分泌IFN-γ的T细胞。和响应于细胞内病原体抗原的IL-2，并任选确定该细胞因子谱中的任何变化。

8. 发明申请

WO2010097564A2 COSMETIC OR PHARMACEUTICAL PREPARATION FOR THE SKIN 审中-公开
标题翻译：化妆品或皮肤的药物制剂
公开(公告)号：WO2010097564A2
公开(公告)日：2010-09-02
申请号：PCT/GB2009002642
申请日：2009-11-11
申请人： TAYLOR ROBERT PETER , LALVANI KARTAR SINGH , LALVANI AJIT
发明人： TAYLOR ROBERT PETER , LALVANI KARTAR SINGH , LALVANI AJIT
IPC分类号： A61K8/06 , A61K8/27 , A61K8/35 , A61K8/55 , A61K8/67 , A61K8/92 , A61K8/97 , A61Q19/00
CPC分类号： A61K8/922 , A61K8/06 , A61K8/27 , A61K8/355 , A61K8/553 , A61K8/671 , A61K8/675 , A61K8/676 , A61K8/678 , A61K8/97 , A61K2800/592 , A61K2800/88 , A61K2800/882 , A61Q19/00 , A61Q19/08
摘要： This invention concerns a cosmetic or pharmaceutical preparation intended for application to skin as a freshly prepared emulsion that can take the form of a cream or lotion. There are two phases that are mixed just prior to use. In its optimal form there is an Aqua Phase that consists of : 4% Liquid Panthenol, 4% Nicotinamide, 0.00125% Riboflavin 5'- Phosphate sodium, 0.4% Zinc Sulphate heptahydrate, 0.01% D-Biotin, 1% Aloe Life Aloe Vera gel Freeze dried powder 20, 0.07% Keltrol SFT CG, 0.5% Thiamine nitrate, 0.2% Lemon Oil X5 fold, 1% Dermican PW LS9838, 0.56% Cremaphor PEG40 Hydrated castor oil, 0.12% Potassium sorbate, and approximately 88% De-mineralised water; and an Oil Phase that consists of: 13.50% Lecithin Emulmetik 100, 10.80% DL-alpha tocopherol, 10.80% Distilled Avocado oil, 5.40% Cosmetic grade Calendula oil, 2.00% Ascorbyl Tetraisopalmitate (Nikkon VC-IP), 0.90% Liquid Silicon, 0.50% Alpha-lipoic acid 99%, 0.20% Jasmine oil, 0.40% Vitamin A palmitate (lM/g) oily, 0.12% Rose oil cosmetic grade, 0.10% Coenzyme Q10 ubidecarenone, 0.10% Orange oil 5 fold extract, 0.076% Lavendar oil, 0.02% Lutein Esters 20% (trans-lutein 10%), and approximately 55% Distilled Wheatgerm oil.
摘要翻译：本发明涉及旨在用于皮肤的化妆品或药物制剂，其作为新鲜制备的可以呈霜剂或洗剂形式的乳剂。有两个阶段在使用之前混合使用。在其最佳形式中有一个水相，包括：4％液体泛醇，4％烟酰胺，0.00125％核黄素5'-磷酸钠，0.4％硫酸锌七水合物，0.01％D-生物素，1％芦荟芦荟凝胶冷冻干粉20,0.07％Keltrol SFT CG，0.5％硝酸硫胺素，0.2％柠檬油X5折，1％Dermican PW LS9838,0.56％Cremaphor PEG40水合蓖麻油，0.12％山梨酸钾和约88％去矿化水 ; 和油相，包括：13.50％卵磷脂Emulmetik 100,10.80％DL-α-生育酚，10.80％蒸馏的鳄梨油，5.40％化妆品级金盏花油，2.00％抗坏血酸四异棕榈酸酯（Nikkon VC-IP），0.90％液体硅， 0.50％α-硫辛酸99％，0.20％茉莉油，0.40％维生素A棕榈酸酯（1M / g），0.12％玫瑰油化妆品级，0.10％辅酶Q10 ubidecarenone，0.10％橙油5倍提取物，0.076％油，0.02％叶黄素20％（反式叶黄素10％）和约55％蒸馏的Wheatgerm油。

9. 发明申请

WO2007107714A3 CLINICAL CORRELATES 审中-公开
标题翻译：临床相关
公开(公告)号：WO2007107714A3
公开(公告)日：2007-11-15
申请号：PCT/GB2007000934
申请日：2007-03-16
申请人： LALVANI AJIT , MILLINGTON KERRY
发明人： LALVANI AJIT , MILLINGTON KERRY
IPC分类号： G01N33/569
CPC分类号： G01N33/5695 , G01N33/56905 , G01N33/56911 , G01N33/56983 , G01N2333/35 , G01N2333/55 , G01N2333/57 , G01N2800/52
摘要： A method of assessing an intracellular pathogen infection and/or monitoring an intracellular pathogen infection in an individual comprises determining whether the individual has (a) T-cells that secrete IFN-? only, (b) T-cells that secrete IL-2 only or (c) T-cells that secrete both IFN-? and IL-2 in response to an intracellular pathogen antigen and optionally determining any change in this cytokine profile.
摘要翻译：评估细胞内病原体感染和/或监测个体中细胞内病原体感染的方法包括确定个体是否具有（a）分泌IFN-γ的T细胞只有（b）仅分泌IL-2的T细胞或（c）分泌IFN-γ的T细胞和IL-2，并且任选地确定该细胞因子谱的任何变化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式